LAUREL DUFFY: Open Payments
NPI 1841982121 · PLYMOUTH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,225 in 51 payments from 14 companies in 2025. Trend: 2023 $338 · 2024 $1,306 · 2025 $1,225
Food & beverage: $1,225
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $313 |
| AstraZeneca Pharmaceuticals LP | 9 | $222 |
| Novartis Pharmaceuticals Corporation | 8 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $85 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Amgen Inc. | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Merck Sharp & Dohme LLC | 1 | $27 |
Products named: Wegovy, JARDIANCE, LEQVIO, AIRSUPRA, Kerendia, FARXIGA, ONPATTRO, REPATHA.
Industry payments across MA — which companies pay providers there.
